Celcuity/CELC

$18.49

6.08%
-
1D1W1MYTD1YMAX

About Celcuity

Celcuity, Inc. is a clinical-stage biotechnology company focused on the development of targeted therapies for treatment of multiple solid tumor indications. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients to benefit from targeted therapies. Its lead therapeutic candidate is gedatolisib, a potent, small molecule dual inhibitor that selectively targets all Class I isoforms of PI3K and mammalian target of rapamycin (mTOR). Its mechanism of action and pharmacokinetic properties are highly differentiated from other investigational therapies that target PI3K or mTOR alone or together. Its initial clinical development program for gedatolisib focus on the treatment of patients with hormone receptor positive (HR+), HER2-negative, advanced or metastatic breast cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer.

Ticker

CELC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Brian Sullivan

Employees

45

Headquarters

Minneapolis, United States

Celcuity Metrics

BasicAdvanced
$421.86M
Market cap
-
P/E ratio
-$2.73
EPS
0.74
Beta
-
Dividend rate

What the Analysts think about Celcuity

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
48.19% upside
High $40.00
Low $20.00
$18.49
Current price
$27.40
Average price target

Celcuity Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-18.4M
26.9%
Profit margin
0%
-

Celcuity Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 21.61%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.69
-$0.55
-$0.66
-$0.83
-
Expected
-$0.44
-$0.52
-$0.60
-$0.68
-$0.73
Surprise
57.71%
6.28%
10.46%
21.61%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Celcuity stock

Buy or sell Celcuity stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing